Clinical Trial Update: Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH) [Phase 1]

View source ↗

Summary

Phase 1 dose-response study of VA106483 in men with nocturia and benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia
• Nocturia

Drugs mentioned

• VA106483

Snippet

Sponsor: Vantia Ltd | Conditions: Nocturia, Benign Prostatic Hypertrophy (BPH) | Phase 1 | Status: COMPLETED